Washington prepares for flu season with first mRNA flu vaccine amid insurance uncertainties
An mRNA-based flu vaccine for adults 50 and older has received FDA approval in Washington, but coverage decisions remain unclear as the ACIP panel is inactive due to ongoing litigation.
The U.S. Food and Drug Administration has approved an mRNA flu vaccine, mFlusiva, for adults aged 50 and older, marking the first use of messenger-RNA technology in seasonal influenza shots. The vaccine, developed by Moderna, instructs cells to produce flu proteins that trigger an immune response, a method similar to that used in COVID-19 vaccines.
The Advisory Committee for Immunization Practices (ACIP), which normally issues recommendations for new vaccines, has not met this year after a lawsuit led to the dismissal of its members. A federal judge ruled that the removal of the panel was likely illegal, and the case is under appeal. As a result, there is currently no ACIP guidance on the new flu shot.
State health officials said the vaccine represents a public-health milestone because mRNA platforms can be adapted more quickly to circulating flu strains, potentially reducing mismatches that have occurred in recent seasons.
Medicare is expected to cover the vaccine for adults 65 and older, and some private insurers may cover it for those 50 to 64, according to the American Health Insurance Plans trade group. However, the Washington Office of the Insurance Commissioner said it has not yet determined coverage policies for the 50-64 age group, and Medicaid coverage may be limited without an ACIP recommendation. The vaccine’s list price is about $171 per dose without insurance.
Health officials continue to recommend that people receive any available flu vaccine, as all provide some protection against severe illness. Updated COVID-19 vaccines are also being offered to individuals six months and older.
State health leaders emphasized the importance of vaccination as respiratory illness visits to emergency departments have risen, with nearly 10% of ER visits in mid-September linked to respiratory symptoms. The Washington Department of Health has also expanded standing orders to allow COVID-19 vaccinations without a prescription for all eligible residents.